Menu Close

Nature Communications Publishes Studies Comparing Triumvira’s T Cell Antigen Coupler (TAC) Technology with CAR T Cell Therapy

Efficacy of Engineered T Cells can be Uncoupled from Toxicities Observed with CAR T Cell Therapy AUSTIN, Texas & HAMILTON, Ontario–(BUSINESS WIRE)–August 3, 2018– Triumvira Immunologics, Inc., (Triumvira) a privately-held biopharmaceutical company … (본문 전체 8/3/2018 7:27 PM)